EAM
Exome Asset Management Portfolio holdings
AUM
$110M
This Quarter Return
+11.92%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$148M
AUM Growth
+$148M
(+32%)
Cap. Flow
+$29.1M
Cap. Flow
% of AUM
19.64%
Top 10 Holdings %
Top 10 Hldgs %
35.62%
Holding
82
New
30
Increased
14
Reduced
8
Closed
23
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
$5.27M |
| 2 |
Align Technology
ALGN
|
$4.76M |
| 3 |
Gilead Sciences
GILD
|
$4.19M |
| 4 |
Geron
GERN
|
$4.11M |
| 5 |
BioNTech
BNTX
|
$4.1M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$5.2M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$4.02M |
| 3 |
Corbus Pharmaceuticals
CRBP
|
$3.84M |
| 4 |
Travere Therapeutics
TVTX
|
$3.64M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$3.03M |
Sector Composition
| 1 | Healthcare | 98.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insmed
INSM
$30.3B
| $2.45M | 1.66% |
33,600
-23,200
| -41% | -$1.69M |
|
27
Legend Biotech
LEGN
$6.64B
| $2.29M | 1.55% |
+47,000
| New | +$2.29M |
|
28
Mersana Therapeutics
MRSN
$34.8M
| $2.23M | 1.51% |
+1,178,570
| New | +$2.23M |
|
29
89bio
ETNB
$1.37B
| $2.22M | 1.5% |
+300,600
| New | +$2.22M |
|
30
Akero Therapeutics
AKRO
$3.65B
| $2.21M | 1.5% |
+77,100
| New | +$2.21M |
|
|
CNTA
31
Centessa Pharmaceuticals
CNTA
$2.13B
| $2.21M | 1.49% |
138,152
-136,748
| -50% | -$2.19M |
|
32
Stoke Therapeutics
STOK
$1.08B
| $2.17M | 1.47% |
+176,600
| New | +$2.17M |
|
33
Amgen
AMGN
$153B
| $2.16M | 1.46% |
6,700
-5,100
| -43% | -$1.64M |
|
34
Guardant Health
GH
$8.11B
| $2.06M | 1.39% |
89,800
+10,800
| +14% | +$248K |
|
35
Nuvalent
NUVL
$5.74B
| $2.04M | 1.38% |
+19,945
| New | +$2.04M |
|
|
RVNC
36
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.8M | 1.22% |
+347,600
| New | +$1.8M |
|
37
Kura Oncology
KURA
$732M
| $1.76M | 1.19% |
90,305
-41,437
| -31% | -$810K |
|
38
Rezolute
RZLT
$630M
| $1.71M | 1.15% |
352,056
+69,656
| +25% | +$338K |
|
39
Pliant Therapeutics
PLRX
$105M
| $1.68M | 1.13% |
149,600
+25,600
| +21% | +$287K |
|
40
Edgewise Therapeutics
EWTX
$1.54B
| $1.6M | 1.08% |
+59,900
| New | +$1.6M |
|
41
STAAR Surgical
STAA
$1.35B
| $1.52M | 1.02% |
+40,800
| New | +$1.52M |
|
42
Tarsus Pharmaceuticals
TARS
$2.44B
| $1.5M | 1.01% |
+45,600
| New | +$1.5M |
|
43
BioCryst Pharmaceuticals
BCRX
$1.74B
| $1.49M | 1.01% |
+196,500
| New | +$1.49M |
|
44
Scholar Rock
SRRK
$3.3B
| $1.12M | 0.75% |
+133,039
| New | +$1.12M |
|
|
TECX
45
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $1.1M | 0.74% |
36,344
+3,955
| +12% | +$120K |
|
46
Alvotech
ALVO
$2.48B
| $1.07M | 0.72% |
90,100
-8,900
| -9% | -$106K |
|
47
Quanterix
QTRX
$202M
| $953K | 0.64% |
73,501
+13,851
| +23% | +$180K |
|
48
Establishment Labs
ESTA
$1.11B
| $939K | 0.63% |
21,700
| – | – |
|
49
Acrivon Therapeutics
ACRV
$42.2M
| $817K | 0.55% |
+116,757
| New | +$817K |
|
50
Lexeo Therapeutics
LXEO
$266M
| $797K | 0.54% |
+88,148
| New | +$797K |
|